RIO DE JANEIRO, BRAZIL - EMS pharmaceutical company advised the Senate's Covid CPI that it invoiced R$142 (US$28.2) million with "Covid kit" drugs in 2020, an amount 8 times higher than the previous year. The sum with the sale of ivermectin alone increased from R$2.2 million to R$71.1 million in the pandemic.
The laboratory also produced azithromycin, hydroxychloroquine, and nitazoxanide, ineffective drugs against the virus, but which became President Jair Bolsonaro's flagship in the health crisis.
In 2020, Bolsonaro asked India's Prime Minister Narendra Modi to release the export of raw . . .